Purpose Cardiac noradrenergic denervation visualized by meta-[123I]iodobenzylguanidine ([123I]MIBG) imaging supports the diagnosis of Parkinson’s disease (PD). Recently, meta-[18F] fluorobenzylguanidine ([18F]MFBG) PET demonstrated favorable imaging characteristics compared with [123I]MIBG scintigraphy for neuroendocrine tumors. We assessed [18F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients. Methods For dosimetry, three controls underwent sequential whole-body [18F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [18F]MFBG PET/CT and two static [123I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3–4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (VT) using a 2-tissue compartment model (2TCM). [18F]MFBG VT was assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [18F]MFBG and [123I]MIBG. Results Mean effective dose was 23.1±2.6 μSv/MBq. [18F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with VT of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM VT from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p<0.001) to 2TCM VT from full 120-min datasets. [18F]MFBG HMR correlated the same to [18F]MFBG VT (ρ=0.88, p=0.007) for 10–30-min as for 100–120-min postinjection time intervals. [123I]MIBG HMR correlated more strongly to [18F]MFBG VT at 3-4h (ρ=0.9, p<0.005) compared to at 15-min (ρ=0.69, p=0.069) postinjection. Conclusion [18F]MFBG PET is a feasible and safe imaging modality for non-invasive and simplified quantification of myocardial sympathetic innervation. Clinical trial registration ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049

[¹⁸F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics

期刊论文
发表日期：

2025年9月9日

查看全文

Louis Versweyveld,
Aline Delva,
Marie Cohilis,
Christophe M. Deroose,
Donatienne Van Weehaeghe,
Michel Koole,
Wim Vandenberghe,
Koen Van Laere

摘要

Purpose

Cardiac noradrenergic denervation visualized by meta-[¹²³I]iodobenzylguanidine ([¹²³I]MIBG) imaging supports the diagnosis of Parkinson’s disease (PD). Recently, meta-[¹⁸F] fluorobenzylguanidine ([¹⁸F]MFBG) PET demonstrated favorable imaging characteristics compared with [¹²³I]MIBG scintigraphy for neuroendocrine tumors. We assessed [¹⁸F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.

Methods

For dosimetry, three controls underwent sequential whole-body [¹⁸F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [¹⁸F]MFBG PET/CT and two static [¹²³I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3–4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (V_T) using a 2-tissue compartment model (2TCM). [¹⁸F]MFBG V_Twas assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [¹⁸F]MFBG and [¹²³I]MIBG.

Results

Mean effective dose was 23.1±2.6 μSv/MBq. [¹⁸F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with V_T of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM V_T from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p<0.001) to 2TCM V_T from full 120-min datasets. [¹⁸F]MFBG HMR correlated the same to [¹⁸F]MFBG V_T (ρ=0.88, p=0.007) for 10–30-min as for 100–120-min postinjection time intervals. [¹²³I]MIBG HMR correlated more strongly to [¹⁸F]MFBG V_T at 3-4h (ρ=0.9, p<0.005) compared to at 15-min (ρ=0.69, p=0.069) postinjection.

Conclusion

[¹⁸F]MFBG PET is a feasible and safe imaging modality for non-invasive and simplified quantification of myocardial sympathetic innervation.

Clinical trial registration

ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049

[18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics

摘要

[¹⁸F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics